Lead Product(s) : SRA737,Aphidicolin,Momelotinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Attacking drug-resistant tumors with Sierra’s struggling CHK1 blocker
Details : Scientists found that combining the drug with another protein inhibitor leads to insurmountable DNA damage that causes cancer cells to die.
Product Name : SRA737
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : SRA737,Aphidicolin,Momelotinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable